Express News | Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025
Arcturus Therapeutics (ARCT) Gets a Hold From Leerink Partners
Arcturus Therapeutics: Promising Phase II Prospects for ARCT-032 in Cystic Fibrosis Amidst Regulatory Approvals
Guggenheim Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Announces Target Price $45
H.C. Wainwright Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $60
Why Investors Shouldn't Be Surprised By Arcturus Therapeutics Holdings Inc.'s (NASDAQ:ARCT) 31% Share Price Plunge
Arcturus Therapeutics Analyst Ratings
Arcturus Gets FDA Fast-Track Designation for Pandemic Influenza A H5N1 Vaccine
Express News | Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the Starr® Mrna Vaccine Candidate Arct-2304 for Pandemic Influenza a Virus H5N1
Express News | Arcturus Therapeutics Holdings Inc : Guggenheim Cuts Target Price to $45.00 From $71.00
Insider Sellers Might Regret Selling Arcturus Therapeutics Holdings Shares at a Lower Price Than Current Market Value
Optimistic Buy Rating for Arcturus Therapeutics Amid Promising Cystic Fibrosis Treatment Developments
BTIG Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Raises Target Price to $58
William Blair Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating
Strategic Growth and Financial Positioning: Arcturus Therapeutics' Promising Outlook Amid Upcoming Trial Data and Financial Adjustments
Despite Revenue Setback, Arcturus Therapeutics (ARCT) Vaccine Breakthroughs Fuel Optimism
Arcturus Therapeutics Is Maintained at Buy by Canaccord Genuity
CCORF Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Cuts Target Price to $68
BTIG Maintains Arcturus Therapeutics(ARCT.US) With Buy Rating, Maintains Target Price $48
Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (PTGX), Halozyme (HALO) and Arcturus Therapeutics (ARCT)